Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region.
Migliori GB, Korotych O, Achar J, Ciobanu A, Dravniece G, Germanovych M, Gurbanova E, Hovhannesyan A, Khachatryan N, Kuksa L, Lomtadze N, Rich ML, Skrahina A, Yedilbayev A. Migliori GB, et al. Among authors: lomtadze n. IJTLD Open. 2024 Mar 1;1(3):103-110. doi: 10.5588/ijtldopen.24.0035. eCollection 2024 Mar. IJTLD Open. 2024. PMID: 38966407 Free PMC article.
Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018.
Buziashvili M, Davtyan H, Sereda Y, Denisiuk O, Gozalov O, Lomtadze N, Hovhannesyan A. Buziashvili M, et al. Among authors: lomtadze n. Monaldi Arch Chest Dis. 2021 Jan 14;91(1):10.4081/monaldi.2021.1649. doi: 10.4081/monaldi.2021.1649. Monaldi Arch Chest Dis. 2021. PMID: 33470083 Free PMC article.
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed S, Algozhin Y, Coutisson S, Garavito ES, Hewison C, Holtzman D, Huerga H, Janmohamed A, Khan PY, Jacques GL, Lomtadze N, Melikyan N, Mitnick CD, Mussabekova G, Osso E, Perea S, Putri FA, Rashidov M, Rich ML, Sakhabutdinova Y, Seung KJ, Stambekova A, Vásquez DV, Franke MF, Khan U. Lotia Farrukh I, et al. Among authors: lomtadze n. Clin Infect Dis. 2024 Jan 25;78(1):144-148. doi: 10.1093/cid/ciad445. Clin Infect Dis. 2024. PMID: 37606512 Free PMC article.
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A. Korotych O, et al. Among authors: lomtadze n. Lancet Infect Dis. 2024 Oct;24(10):1151-1161. doi: 10.1016/S1473-3099(24)00228-7. Epub 2024 Jun 13. Lancet Infect Dis. 2024. PMID: 38880112 Free PMC article.
Setting up pharmacovigilance based on available endTB Project data for bedaquiline.
Lachenal N, Hewison C, Mitnick C, Lomtadze N, Coutisson S, Osso E, Ahmed S, Leblanc G, Islam S, Atshemyan H, Nair P, Kholikulov B, Aiylchiev S, Zarli K, Adnan S, Krisnanda A, Padayachee S, Stambekova A, Sahabutdinova Y, de Guadalupe S, Moreno P, Kumsa A, Reshid A, Makaka J, Abebe S, Melikyan N, Seung KJ, Khan U, Khan P, Huerga H, Rich M, Varaine F. Lachenal N, et al. Among authors: lomtadze n. Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1087-1094. doi: 10.5588/ijtld.20.0115. Int J Tuberc Lung Dis. 2020. PMID: 33126944
Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L, Kempker RR, Chakhaia TS, Bablishvili N, Avaliani Z, Lomtadze N, Schechter MC, Kipiani M. Mikiashvili L, et al. Among authors: lomtadze n. Clin Infect Dis. 2024 Apr 10;78(4):1043-1052. doi: 10.1093/cid/ciad694. Clin Infect Dis. 2024. PMID: 37962987 Free PMC article.
Low BMI increases all-cause mortality rates in patients with drug-resistant TB.
Adamashvili N, Baliashvili D, Kuchukhidze G, Salindri AD, Kempker RR, Blumberg HM, Lomtadze N, Avaliani Z, Magee MJ. Adamashvili N, et al. Among authors: lomtadze n. Int J Tuberc Lung Dis. 2022 Apr 1;26(4):326-333. doi: 10.5588/ijtld.21.0450. Int J Tuberc Lung Dis. 2022. PMID: 35351237 Free PMC article.
22 results